Bristol Myers Squibb Raises 2024 Non-GAAP Guidance

(RTTNews) – Bristol Myers Squibb (BMY) increased portions of its 2024 line-item guidance. The company now expects: non-GAAP EPS in a range of $0.60 – $0.90, revised from prior guidance range of $0.40 – $0.70; and total revenues at upper end of low single- digit range, revised fro